Camlin Fine Sciences Stock Tanks 18% After Q2 Results, Hits 52-Week Low

Camlin Fine Sciences Faces a Margin Test After a Weak Quarter

Revenue growth offered little comfort as higher costs and liquidity constraints sharply squeezed profitability.

Revenue rose, but cost pressures overwhelmed the quarter

Camlin Fine Sciences reported revenue of ₹491.5 crore for the quarter ended September 2026, up 9.15 per cent year on year. That growth did not translate into stronger earnings: gross margin fell to 39.8 per cent from 46.5 per cent a year earlier, as higher raw-material prices and limited pass-through weighed on profitability. The company also cited liquidity issues as an additional constraint.

EBITDA dropped to ₹2.23 crore from ₹35.63 crore, while the EBITDA margin contracted to 0.45 per cent from 7.91 per cent. Camlin Fine Sciences reported a net loss of ₹28.08 crore, compared with a loss of ₹1.87 crore in Q2FY26. The gap between revenue growth and operating performance is central to the results: higher sales were not enough to offset the cost burden.

The company also pointed to increased freight expenses, longer transit times and extended working-capital cycles. These pressures can affect both operating costs and the timing of cash coming into the business, making liquidity an important part of the recovery question alongside demand and pricing.

The share-price fall reflects a sharp reset in expectations

The shares fell as much as 18 per cent intraday to ₹75.05, below the previous 52-week low of ₹79. At 12:36 PM, they were down 17 per cent at ₹75.90, while the Sensex was lower by 0.03 per cent. Combined trading volume on the NSE and BSE reached 4.55 million shares, about three times the average.

The stock had already fallen 63 per cent from its 52-week high of ₹202.55. The latest decline came alongside the results, rather than a broad-market move of similar scale. For investors, the quarter raises questions about how quickly margins and cash flows can recover; the share-price move itself does not resolve those operating concerns.

Rights issue could ease liquidity pressure, if executed

The board approved a fundraise of up to ₹250 crore through a rights issue to address liquidity challenges. Axis Securities said the proposed capital could support working-capital normalisation, including settling overdue creditors, and reduce reliance on expensive channel financing. Those are potential benefits, not outcomes assured by the approval: execution of the issue and the use of proceeds will matter.

The brokerage expects performance in Q3FY27 to remain broadly at Q2 levels and cites a possible recovery in Q4FY27, with revenue above ₹600 crore and EBITDA of at least ₹60 crore. It has maintained a Buy rating but cut its target price to ₹145 from ₹165. Its outlook depends on the rights issue, improving cash flows and a recovery in operating margins, so the targets should be viewed as estimates rather than assured results.

Blends and aroma offer different recovery paths

The brokerage sees healthy growth in the blends business, supported by demand across food, feed, pet food and functional ingredients. It expects blends margins to improve from 11–12 per cent to 13–14 per cent in the near term, and later to 14–15 per cent. These projections would support profitability if achieved, but the reported quarter underscores how cost inflation can offset business growth.

The aroma business faces a different set of pressures, including a transition from Ethyl Vanillin to Methyl Vanillin, lower capacity utilisation and pricing pressure from excess Chinese-origin inventory. Management expects the inventory overhang to ease by the end of CY26 and is targeting quarterly Vanillin volumes of around 1,000 MT from Q4FY27. Axis Securities estimates that this volume could add ₹65–70 crore in quarterly revenue; actual recovery will depend on volumes and realisations improving.

Key Highlights

• Q2 revenue increased 9.15 per cent year on year to ₹491.5 crore.
• EBITDA fell to ₹2.23 crore and the company reported a net loss of ₹28.08 crore.
• Gross margin contracted to 39.8 per cent amid raw-material and operating-cost pressures.
• The board approved a rights issue of up to ₹250 crore to address liquidity challenges.
• Blends growth, aroma volumes and cash-flow improvement are key recovery monitorables.

Investor Note: Camlin Fine Sciences’ recovery case rests on more than revenue growth: investors may want to track whether the rights issue is completed, working-capital pressures ease and margins improve across its businesses. Brokerage forecasts are conditional, and the latest results show that execution and cost control remain significant risks.